Aptinyx

Aptinyx Equity

Delisted

The The Equity of Aptinyx (APTX) as of Nov 5, 2026 is 38.29 M USD. In the previous year, The Equity was 94.76 M USD — a change of -59.60% (lower).

Equity

38.29 MUSD

YoY

-59.60%

Last updated:

In 2022, Aptinyx's equity was 38.29 M USD, a -59.60% increase from the 94.76 M USD equity in the previous year.

The Aptinyx Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2016
-8.55 M USD
Jan 1, 2017
-39.72 M USD
Jan 1, 2018
149.31 M USD
Jan 1, 2019
101.31 M USD
Jan 1, 2020
145.91 M USD
Jan 1, 2021
94.76 M USD
Jan 1, 2022
38.29 M USD
The Aptinyx Equity history
YEAREquityYoY
38.29 MUSD-59.60%
94.76 MUSD-35.06%
145.91 MUSD+44.02%
101.31 MUSD-32.15%
149.31 MUSD-475.93%
-39.72 MUSD+364.48%
-8.55 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Aptinyx Stock analysis

What does Aptinyx do? Aptinyx Inc is a biopharmaceutical company specializing in the development of therapies for the treatment of neurological diseases. The company was founded in 2015 in Evanston, Illinois, USA, and has since achieved an impressive track record in researching and developing innovative therapies. The history of Aptinyx Inc begins with a group of experienced scientists and researchers who came together to push the boundaries of neuroscience research and discover new treatment options for people with brain disorders. The company is based on the belief that the human brain is a fascinating and complex entity that still holds many secrets. The company is committed to improving human well-being through innovative neurotherapeutic products and services. Aptinyx Inc's business model focuses on the research, development, and commercialization of novel therapeutic treatments for neurological diseases. The company closely collaborates with leading academic institutions and facilities to leverage the best research findings and methods. The company has a strong scientific foundation led by an experienced team of researchers and developers working on innovative biomarker and therapy strategies. Aptinyx Inc has focused on the development of neuromodulators and neuroprotectants to treat neurological diseases, including pain disorders, peripheral neuropathies, neuropathic pain, Parkinson's disease, post-traumatic stress disorder (PTSD), and other central nervous system disorders. Aptinyx Inc's products are based on a comprehensive understanding of the fundamentals of the nervous system and how it functions. The company offers a variety of products and services, including novel therapeutics for the treatment of pain, neuropathy, and other neurological diseases. These products are based on the utilization of Aptinyx's proprietary technologies to selectively modulate specific cell types and signaling pathways in the nervous system. The products and services of Aptinyx Inc have been regulated by leading health authorities in the US and Europe. Aptinyx Inc has two main divisions of products: the first focus is on the development of neuromodulators that specifically alleviate pain and modulate the brain. The second focus is on the development of neuroprotectants that help protect neurons and reduce inflammation in the nervous system. These two divisions are closely interconnected as they are based on a common platform grounded in the exploration of novel biomarkers and therapeutic targets. The products of Aptinyx Inc are designed for both pain relief and improvement of neural functions. Additionally, these products aim to enhance patient experience and quality of life. The company consistently collaborates with potential partners and experts to develop products tailored to the needs of patients and healthcare providers. Overall, Aptinyx Inc has revolutionized the world of neuroscience by exploring and developing innovative solutions for neurological diseases. The company has achieved an impressive track record by utilizing its scientific expertise and groundbreaking technologies to set new trends in neuroscience research and therapeutics. In summary, Aptinyx Inc has developed a unique approach to the development of neuromodulators and neuroprotectants based on a deep understanding of the structure and function of the nervous system. The products and services of the company have the potential to play a significant role in improving the quality of life for patients with neurological diseases. Aptinyx is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Aptinyx's Equity

Aptinyx's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Aptinyx's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Aptinyx's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Aptinyx's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Aptinyx’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Aptinyx stock

The Equity of Aptinyx is 38.29 M USD in 2022.

The Equity of Aptinyx changed from 94.76 M USD to 38.29 M USD, representing a -59.60% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity Aptinyx since 2006 – with annual values, charts, and detailed analysis.

The Equity's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Aptinyx historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Aptinyx

All Key Metrics — Aptinyx